Eben Tessari Sells 12,368 Shares of Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Key Points

• Eben Tessari, the COO of Kiniksa Pharmaceuticals, sold 12,368 shares of the company's stock for a total of $465,902.56, resulting in a 30.13% decrease in his ownership.
• Kiniksa Pharmaceuticals reported $156.80 million in revenue for the last quarter, exceeding expectations, with an earnings per share of $0.23, beating the consensus estimate by $0.05.
• Analysts have increased price targets for Kiniksa Pharmaceuticals, with several firms rating the stock as a "buy" and setting targets as high as $60.00.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 12,368 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $37.67, for a total value of $465,902.56. Following the sale, the chief operating officer owned 28,684 shares in the company, valued at $1,080,526.28. This represents a 30.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Eben Tessari also recently made the following trade(s):

• On Monday, September 29th, Eben Tessari sold 42,000 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $38.33, for a total value of $1,609,860.00.
• On Monday, September 15th, Eben Tessari sold 16,400 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $36.46, for a total transaction of $597,944.00.
• On Thursday, September 4th, Eben Tessari sold 85,271 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $35.52, for a total transaction of $3,028,825.92.
• On Friday, September 5th, Eben Tessari sold 13,389 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.66, for a total transaction of $477,451.74.
• On Wednesday, September 3rd, Eben Tessari sold 15,091 shares of Kiniksa Pharmaceuticals International stock. The shares were sold at an average price of $35.50, for a total value of $535,730.50.
• On Monday, August 18th, Eben Tessari sold 16,200 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $33.77, for a total value of $547,074.00.
• On Tuesday, August 5th, Eben Tessari sold 138,614 shares of Kiniksa Pharmaceuticals International stock. The stock was sold at an average price of $33.20, for a total transaction of $4,601,984.80.

Kiniksa Pharmaceuticals International Price Performance

NASDAQ KNSA traded up $0.06 during mid-day trading on Thursday, reaching $38.92. The stock had a trading volume of 559,627 shares, compared to its average volume of 633,778. The stock has a market cap of $2.88 billion, a PE ratio of 973.24 and a beta of 0.16. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.82 and a 1 year high of $39.43. The company has a fifty day moving average price of $35.61 and a 200 day moving average price of $29.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The firm had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on KNSA shares. Jefferies Financial Group lifted their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Wedbush raised their target price on Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the stock an "outperform" rating in a research report on Monday. TD Cowen initiated coverage on shares of Kiniksa Pharmaceuticals International in a research report on Monday, September 29th. They set a "buy" rating and a $60.00 price target for the company. Weiss Ratings reissued a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, October 8th. Finally, Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 6th. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $45.43.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its position in shares of Kiniksa Pharmaceuticals International by 4,003.9% in the first quarter. GAMMA Investing LLC now owns 27,496 shares of the company's stock worth $611,000 after purchasing an additional 26,826 shares during the period. Rhumbline Advisers lifted its stake in shares of Kiniksa Pharmaceuticals International by 6.4% during the 1st quarter. Rhumbline Advisers now owns 62,700 shares of the company's stock valued at $1,393,000 after buying an additional 3,745 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in Kiniksa Pharmaceuticals International in the 1st quarter worth $301,000. Asset Management One Co. Ltd. bought a new position in Kiniksa Pharmaceuticals International in the 1st quarter worth $41,000. Finally, Wealthquest Corp purchased a new stake in Kiniksa Pharmaceuticals International in the 1st quarter worth $42,000. Institutional investors own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.